1 	|BT| (S (NP (DT The) (NN CDX2) (NN expression) (JJ gastric) (NN cancer)) (ADVP (RB also)) (ADVP (RB inversely)) (VP (VBD correlated) (NP (NN expression) (JJ gastric) (NN mucin)))) |ET| |BS|72:D12.776.395.560.631.100|ES| 5:1 18:1 19:1 86:1 114:1 115:1 209:1 418:1 446:1 691:1
1 	|BT| (NP (NP (DT The) (NN ECM-modulator) (NN inter)) (: -) (S (NP (NP (NN alpha-trypsin) (NN inhibitor) (JJ heavy) (NN chain) (NN family) (NN member)) (CD five) (-LRB- -LRB-) (NN ITIH5) (-RRB- -RRB-)) (ADVP (RB recently)) (VP (VBD identified) (NP (NP (NN tumor) (NN suppressor)) (VP (ADVP (RB potentially)) (VP (VBN involved) (NP (NP (VBG impairing) (NN breast) (NN cancer) (NN progression) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (S (NP (NN function)) (ADJP (ADVP (RB still)) (JJ elusive))))))))))) |ET| |BS|16:C23.550.291.656 44:F01.829.263 206:G05.360.340.024.340.375.249 223:A11.284.295.310|ES| 7:1 10:1 14:1 18:1 19:1 23:1 33:1 48:1 97:1 161:1 162:1 380:1 435:1 623:1 691:1 700:1 764:1 765:1 766:1 767:1 768:1 769:1 770:1 771:1 772:1 773:1 774:1 775:1 776:1 777:1
1 	|BT| (S (NP (DT The) (NN effect) (NN folate) (NN transporter) (NN gene) (NN ablation) (NN colon) (NN carcinogenesis)) (VP (VBD evaluated) (NP (NP (CD 8) (CD 38) (NN week)) (JJ post-azoxymethane) (NN injection) (JJ wild-type) (JJ heterozygous) (NN mouse)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 157:G05.380.383 224:D03.438.733.631.400 225:E05.337 226:E02.319.267.530 227:D12.776.157.530|ES| 8:1 9:1 19:1 52:1 75:1 91:1 113:1 207:1 691:1 778:1 779:1 780:1 781:1 782:1 783:1 784:1 785:1 786:1
1 	|BT| (FRAG (NP (NP (DT The) (NN level) (NN miR-221) (NN miR-222)) (RRC (ADVP (RB well)) (NP (NP (NN RelA)) (, ,) (NP (NN STAT3)) (, ,) (NP (NP (NN PDLIM2) (NNS mRNAs)) (VP (VBN measured) (NP (CD 57) (JJ paired) (NN CRC) (JJ adjacent) (JJ nontumor) (NN tissue) (NN patient)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 82:D12.644.360.024.342.300 98:A10 111:D13.444.735.544 228:E05.978|ES| 2:1 19:1 120:1 126:1 140:1 141:1 245:1 249:1 250:1 251:1 272:1 326:1 445:1 447:1 691:1 787:1 788:1 789:1 790:1
1 	|BT| (NP (NP (DT The) (NN role) (NN KCNQ1) (NN mouse) (JJ human) (JJ gastrointestinal) (NN cancer))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 55:B01.050.150.900.649.801.400.112.400.400|ES| 18:1 19:1 31:1 36:1 52:1 183:1 691:1 791:1
1 	|BT| (S (NP (DT These) (NNS data)) (VP (VP (VBP provide) (NP (NN evidence) (NN Cdx2) (VP (VBZ antagonizes) (NP (NN process) (NN tumor) (NN cell) (NN dissemination))))) (, ,) (VP (VBP suggest) (SBAR (S (NP (NN homeobox) (NN gene)) (VP (MD might) (VP (VB represent) (NP (JJ new) (JJ therapeutic) (NN target) (JJ metastatic) (NN spreading) (NN colon) (NN cancer))))))))) |ET| |BS|8:C04 52:E02 229:G05.360.340.024.340.230.500 230:G04|ES| 2:1 7:1 9:1 18:1 19:1 38:1 94:1 113:1 160:1 213:1 337:1 541:1 638:1 711:1 712:1 792:1 793:1 794:1 795:1 796:1 797:1 798:1 799:1 800:1
1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (NP (S (NP (NN K-sam) (NN overexpression)) (VP (VBN associated) (NP (JJ malignant) (NN phenotype) (JJ undifferentiated) (NN type) (NN stomach) (NN cancer)))) (, ,) (NP (JJ infiltrative) (NN growth) (NN metastasis)))))) |ET| |BS|45:G07.700.320.249 80:G05.695 113:C04.697.650 231:C04.557.465.625.600.380.590 232:D02.886.030.676.180|ES| 2:1 18:1 19:1 101:1 102:1 152:1 169:1 236:1 543:1 792:1 796:1 801:1 802:1 803:1 804:1 805:1 806:1
1 	|BT| (S (S (NP (DT This) (JJ K-Ras) (NN tumor) (NN phenotype)) (VP (VBN associated) (VP (VBD attenuated) (NP (NN signaling) (NN MAPK) (NN pathway))))) (, ,) (NP (JJ human) (NN colon) (NN cancer) (NN cell)) (VP (VBG expressing) (NP (NP (JJ mutant) (NN K-Ras) (JJ hypersensitive) (NN inhibition) (NN Raf)) (, ,) (NP (NN Mek))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 41:A11 43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 80:G05.695 233:D08.811.913.696.620.682.700.565 234:D08.811.913.696.620.682.700.565|ES| 2:1 7:1 13:1 18:1 19:1 36:1 94:1 103:1 113:1 169:1 195:1 236:1 383:1 807:1 808:1 809:1 810:1 811:1 812:1 813:1 814:1
1 	|BT| (S (NP (DT This) (NN study)) (VP (VBZ provides) (SBAR (S (NP (NP (JJ first) (JJ quantitative) (NN analysis) (JJ discrete) (NN CRKI) (NN CRKII) (NN protein) (NNS isoforms)) (SBAR (S (NP (JJ human) (NN lung) (NN tumor)) (VP (VBZ provides) (NP (NN evidence) (NN C-CRK) (NN proto-oncogene)))))) (VP (MD may) (VP (VB foment) (NP (JJ aggressive) (NN phenotype) (NN lung) (NN cancer)))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 80:G05.695 162:F01.145.126.125 235:G05.360.340.024.340.375.500.791 236:D12.644.360.024.318 237:C04.588.894.797.520 238:D12.776.800|ES| 4:1 7:1 18:1 19:1 36:1 38:1 131:1 236:1 328:1 491:1 538:1 563:1 661:1 807:1 815:1 816:1 817:1 818:1 819:1 820:1 821:1 822:1 823:1
1 	|BT| (S (NP (DT This) (NN study)) (VP (VBP show) (SBAR (S (NP (NN c-Myc) (JJ critical) (JJ Apc-dependent) (JJ intestinal) (NN tumorigenesis) (NN mouse)) (VP (VBZ provides) (NP (JJ potential) (JJ therapeutic) (NN target) (NN treatment) (JJ colorectal) (NN cancer))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 47:A03.556.124 52:E02|ES| 17:1 18:1 19:1 52:1 78:1 109:1 131:1 160:1 429:1 541:1 546:1 807:1 815:1 824:1 825:1 826:1 827:1
1 	|BT| (S (S (S (VP (TO To) (VP (VB understand) (NP (NN miR-141))))) (VP (VBZ mediates) (NP (NN phenotype) (JJ pancreatic) (NN cancer) (NN cell)))) (S (, ,) (NP (NNS bioinformatics) (NN tool)) (VP (VBN used) (VP (VBP identify) (NP (NN MAP4K4) (JJ potential) (NN target) (NN miR-141)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 80:G05.695 239:F02.463.188.357 240:H01.158.273.180|ES| 2:1 18:1 19:1 94:1 160:1 236:1 463:1 465:1 467:1 476:1 755:1 827:1 828:1 829:1 830:1 831:1 832:1
1 	|BT| (FRAG (PP (TO To) (NP (VB investigate) (NP (NP (NN role) (NN KCNQ1) (JJ human) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN measured) (NN protein) (NN level) (NN KCNQ1) (NN immunohistochemistry) (NN tissue) (NNS microarrays)) (VP (VBG containing) (NP (NP (NN sample) (NN CRC) (NN patient) (NN liver) (NN metastasis)) (VP (VBN undergone) (NP (JJ hepatic) (NN resection))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 38:Z01.058.290.120.180 40:Z01.542.248.700 50:M01.643 55:B01.050.150.900.649.801.400.112.400.400 98:A10 113:C04.697.650 143:E01.370.225.500.607.512 228:E05.978 241:D12.776.157.530.400.600.900.124.249.500 242:A03.620|ES| 2:1 4:1 10:1 14:1 17:1 18:1 19:1 31:1 36:1 120:1 128:1 245:1 249:1 272:1 286:1 459:1 789:1 791:1 806:1 828:1 833:1 834:1 835:1 836:1 837:1 838:1
1 	|BT| (NP (NP (NP (JJ Transient) (JJ stable) (NN overexpression) (NN mir-660)) (S (VP (VBG using) (S (NP (NN miRNA)) (VP (VBP mimic) (SBAR (S (NP (VBN reduced) (NP (NN migration)) (, ,) (NP (NN invasion)) (, ,) (NP (NN proliferation) (NN property))) (VP (VBD increased) (NP (NP (NN apoptosis) (NN p53) (JJ wild-type) (NN lung) (NN cancer) (NN cell)) (PRN (-LRB- -LRB-) (NP (NP (NN NCI-H460)) (, ,) (NP (NN LT73)) (, ,) (NP (NN A549))) (-RRB- -RRB-)))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 120:I01.409.418.750.600.480.150 184:D13.150.650.319|ES| 2:1 8:1 10:1 12:1 14:1 18:1 19:1 47:1 89:1 94:1 152:1 299:1 328:1 350:1 360:1 363:1 364:1 373:1 452:1 514:1 567:1 620:1 839:1 840:1 841:1 842:1
1 	|BT| (S (NP (PRP We)) (VP (VBD aimed) (VP (VB investigate) (SBAR (IN whether) (S (NP (NN Notch1) (NN signaling)) (VP (VBZ contributes) (NP (NN carcinogenesis) (JJ gastric) (NN cancer) (NN CD133) (NN induction)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 69:G02.111.087.800|ES| 18:1 19:1 86:1 195:1 207:1 221:1 459:1 651:1 652:1 736:1 843:1 844:1 845:1
1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (JJ biological) (NN function) (NP (NP (JJ related) (JJ molecular) (NN mechanism) (NN PAX5) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) |ET| |BS|104:C04.557.470.200.025.255 141:G16.100 243:D12.776.260.645.500|ES| 10:1 14:1 19:1 33:1 161:1 162:1 303:1 304:1 324:1 419:1 440:1 441:1 843:1 846:1
1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (NN apobec-1) (NN gene) (NN expression) (JJ human) (JJ gastrointestinal) (NN tumor) (NN colon) (JJ cancer-derived) (NN cell) (NN line)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 155:G05.355.310 244:C04.588.274.476|ES| 7:1 9:1 19:1 36:1 94:1 113:1 115:1 183:1 264:1 324:1 843:1 847:1 848:1
1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (NN rat) (NN model)) (VP (VBG carrying) (NP (JJ knockout) (NN allele) (NN gatekeeper) (NN gene) (NNP Adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN Apc) (-RRB- -RRB-)))) (VP (VBZ recapitulates) (NP (NP (JJ familial) (NN colon) (NN cancer)) (JJ human) (S (ADVP (RB closely)) (VP (VBG existing) (NP (JJ murine) (NN model)))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 21:G05.360.340.024.340.375.249.050 44:F01.829.263 55:B01.050.150.900.649.801.400.112.400.400 77:G05.360.340.024.340.030 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 247:G01.374.676.530 248:E05.393.335.750|ES| 9:1 10:1 14:1 18:1 19:1 36:1 58:1 59:1 71:1 72:1 113:1 221:1 230:1 280:1 403:1 627:1 843:1 849:1 850:1 851:1 852:1 853:1 854:1 855:1 856:1
1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NN microRNA) (NN miR-221) (NN miR-222)) (VP (VBP regulate) (NP (NP (NP (NN NF-kappaB) (NN signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (NP (NN activation) (JJ human) (NN CRC) (NN cell) (NN line)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 184:D13.150.650.319 210:D12.776.260.600 249:G05.355.315.800 250:E07.305.812|ES| 10:1 14:1 19:1 36:1 94:1 140:1 141:1 221:1 225:1 245:1 251:1 264:1 403:1 487:1 714:1 843:1 857:1 858:1 859:1 860:1 861:1 862:1
1 	|BT| (S (NP (PRP We)) (VP (VBD wanted) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (JJ genetic) (NN defect) (JJ relevant) (JJ colorectal) (NN cancer)) (, ,) (NP (NN Msh2) (NN p53) (NN deficiency)) (, ,)) (VP (MD would) (VP (VB influence) (NP (NN efficiency) (NN sulindac) (NN chemoprevention) (NN increase) (NN side) (NN effect))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 87:C18.654.521 251:D02.455.426.559.847.486.875 252:F02.784.692.351 253:E02.319.162 254:C16.131|ES| 2:1 12:1 17:1 18:1 19:1 40:1 74:1 75:1 221:1 253:1 585:1 588:1 843:1 863:1 864:1 865:1 866:1 867:1 868:1 869:1 870:1 871:1
1 	|BT| (S (NP (NP (NP (NN Western) (NN blot) (JJ quantitative) (JJ real-time) (NN PCR)) (PRN (-LRB- -LRB-) (NP (NN qRT-PCR)) (-RRB- -RRB-))) (NN analysis)) (VP (VBD revealed) (SBAR (S (NP (NN MAP4K4) (NN expression)) (VP (ADVP (RB inversely)) (VBD correlated) (NP (NN miR-141) (NN expression) (JJ pancreatic) (NN cancer) (NN sample) (NN cell) (NN line))))))) |ET| |BS|94:A11.251.210 255:E05.196.401.143 256:E05.196.401.143 257:E05.393.620.500.706|ES| 10:1 14:1 18:1 19:1 94:1 115:1 264:1 275:1 418:1 446:1 463:1 465:1 467:1 661:1 817:1 835:1 872:1 873:1 874:1 875:1 876:1
1 	|BT| (S (NP (NN Western) (NN blot)) (VP (VBD revealed) (NP (NP (NN overexpression) (NN beta-catenin)) (, ,) (NP (NP (NN c-Myc)) (, ,) (NP (NN cyclin) (NN D1)) (, ,) (NP (JJ inducible) (JJ nitric) (NN oxide) (NN synthase)) (NP (NN cyclooxygenase-2) (NN colon) (NN tumor) (NN sample)))))) |ET| |BS|22:D08.811.682.664.500.772.500 23:D12.776.091.249 24:D08.811.600.720.750 51:C04.588.274.476.411.307.180 215:D12.644.360.262.150.100 255:E05.196.401.143|ES| 2:1 7:1 19:1 60:1 61:1 63:1 64:1 65:1 66:1 113:1 152:1 275:1 743:1 744:1 824:1 835:1 872:1 873:1
1 	|BT| (S (NP (NN Wnt/beta-catenin) (NN signaling) (JJ critical) (JJ intestinal) (NN cell) (NN proliferation)) (, ,) (VP (VBD decreased) (NP (NN CDX2) (NN expression) (NN influence) (NN Wnt) (JJ signaling-related) (NN gene) (NN progression) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 16:C23.550.291.656 47:A03.556.124 69:G02.111.087.800 105:G02.149.115.800.925 183:G04.299.233.750|ES| 2:1 9:1 17:1 18:1 19:1 48:1 94:1 109:1 114:1 115:1 195:1 202:1 299:1 302:1 825:1 867:1 877:1 878:1
1 	|BT| (S (NP (NN YY1)) (VP (VBZ promotes) (NP (NP (NN colon) (NN cancer) (NN growth)) (VP (VBG inhibiting) (NP (NP (NN p53)) (S (VP (VBG promoting) (NP (NN Wnt) (NN signaling) (NN pathway) (NN serf) (JJ independent) (JJ prognostic) (NN biomarker) (NN CRC) (NN patient))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 45:G07.700.320.249 50:M01.643 122:C14.280.383 147:G02.149.115.800.925 158:D23.101 258:D12.776.260.235.875|ES| 12:1 18:1 19:1 102:1 113:1 120:1 195:1 245:1 298:1 383:1 877:1 879:1 880:1 881:1 882:1 883:1 884:1 885:1
-1 	|BT| (S (NP (JJ Ectopic) (NN reactivation) (NN miR-184)) (VP (VBD inhibited) (SBAR (S (NP (NP (NN proliferation) (NP (NP (JJ self-renewal) (JJ triple) (JJ negative) (NN breast) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN TNBC)) (-RRB- -RRB-))) (NN cell) (NN line) (NN vitro)) (VP (VBN delayed) (NP (JJ primary) (NN tumour) (NN formation)))) (VP (VBD reduced) (NP (JJ metastatic) (NN burden) (FW vivo))))))) |ET| |BS|8:C04 20:G03.495 122:C14.280.383 160:C04.588.180.788 543:G04.299.134.220.235|ES| 10:1 14:1 18:1 19:1 23:1 43:1 94:1 216:1 264:1 299:1 305:1 337:1 344:1 365:1 378:1 449:1 452:1 537:1 1011:1 1716:1 1913:1 1914:1 1915:1 1916:1 1917:1
-1 	|BT| (NP (NP (JJ Epigenetic) (NN inactivation) (JJ paired) (NN box) (NN gene) (CD 5)) (, ,) (NP (JJ novel) (NN tumor) (NN suppressor) (NN gene)) (, ,) (NP (NP (JJ direct) (NN upregulation) (NN p53)) (NP (VBN associated) (NN prognosis) (JJ gastric) (NN cancer) (NN patient)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 42:G05.355.315.203.374 50:M01.643 163:E01.789 206:G05.360.340.024.340.375.249 249:G05.355.315.800 259:D12.776.395.240.150.500 339:G02.111.087.880|ES| 2:1 7:1 9:1 12:1 18:1 19:1 86:1 120:1 169:1 544:1 578:1 700:1 790:1 891:1 1126:1 1201:1 1314:1 1891:1 1918:1
-1 	|BT| (NP (NP (NP (NN ERBB4) (NN alteration)) (NP (NP (NP (DT The) (NN Cancer) (NNP Genome) (NNP Atlas) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NP (NP (NN data) (NN set) (JJ stratified) (NN survival)) (, ,) (VP (VBN combined) (S (NP (NNP Moffitt) (NNP Cancer) (NNP Center) (NNP Vanderbilt) (NNP Medical) (NNP Center) (NN CRC) (NN expression) (NNS data)) (VP (VBN set) (, ,) (SBAR (S (NP (NN ERBB4) (NN message) (NN level)) (VP (VBD increased) (NP (NN tumor) (NN stage)))))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 96:I03.784 97:V02.302 269:G05.360.340 544:A02.835.232.834.151.500 545:F02.463.425.838 546:V02.150|ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 47:1 115:1 164:1 245:1 249:1 274:1 691:1 793:1 951:1 1129:1 1679:1 1919:1 1920:1 1921:1 1922:1 1923:1 1924:1 1925:1 1926:1 1927:1 1928:1
-1 	|BT| (S (ADVP (RB Finally)) (, ,) (NP (NN Apo-FHL2) (NN mouse)) (VP (VBD developed) (SBAR (S (NP (NP (NN tumor)) (, ,) (NP (NN FHL2) (NN transgene))) (VP (VBD enhanced) (SBAR (S (NP (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (JJ liver-specific) (NN deletion) (NP (NP (JJ adenomatous) (NN polyposis) (NN coli) (NN gene) (JJ aberrant) (NN Wnt/beta-catenin) (NN signaling) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN lox/lox)) (-RRB- -RRB-))) (NN animal)))))))))) |ET| |BS|3:C04.557.470.035.215.100 8:C04 11:B01.050.150.900.649.865.635.505.500 19:B01.050 21:G05.360.340.024.340.375.249.050 105:G02.149.115.800.925 242:A03.620 547:G05.360.340.024.340.825 548:D08.811.682.664.500.848 549:G05.355.600.800.320|ES| 2:1 7:1 9:1 10:1 14:1 19:1 46:1 52:1 57:1 58:1 59:1 195:1 280:1 302:1 385:1 412:1 900:1 1059:1 1165:1 1725:1 1799:1 1929:1 1930:1 1931:1 1932:1 1933:1
-1 	|BT| (S (NP (JJ Further) (NN study) (NN mechanism) (NN ADCY3) (NN tumorigenesis)) (VP (VBP provide) (NP (NN basis) (JJ new) (JJ molecular) (NN target) (JJ gastric) (NN cancer)))) |ET| |BS|32:C04.697.098.500 33:C04.697.098|ES| 18:1 19:1 78:1 86:1 131:1 160:1 161:1 162:1 330:1 711:1 712:1 1140:1 1934:1
-1 	|BT| (S (ADVP (RB Furthermore)) (NP (NP (NN strategy)) (VP (VBN designed) (VP (VB restore) (NP (NN expression) (NN PTEN))))) (VP (MD may) (S (VP (VBG promising) (NP (NP (NN therapy)) (VP (VBG preventing) (NP (NN HCV) (JJ dependent) (NN hepatocarcinogenesis)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 550:B04.450.410|ES| 19:1 115:1 130:1 321:1 334:1 491:1 900:1 1114:1 1517:1 1683:1 1935:1 1936:1 1937:1 1938:1
-1 	|BT| (S (NP (NN Germ-line) (NN mutation) (NN APC) (NN gene)) (VP (NN cause) (SBAR (S (NP (NP (JJ adenomatous) (NN polyposis) (NN coli) (PRN (-LRB- -LRB-) (NP (NN APC)) (-RRB- -RRB-))) (, ,) (NP (NN syndrome) (NN patient))) (VP (VBP develop) (NP (CD hundred) (CD thousand) (JJ precancerous) (JJ adenomatous) (JJ colorectal) (NN polyp))))))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 21:G05.360.340.024.340.375.249.050 50:M01.643 341:C04.834 551:C04.557.470.035.215 552:G05.365.590.350 553:C23.550.288.500|ES| 2:1 9:1 10:1 11:1 14:1 17:1 19:1 34:1 57:1 58:1 59:1 120:1 647:1 648:1 1130:1 1779:1 1939:1 1940:1 1941:1 1942:1
-1 	|BT| (S (S (ADVP (RB Hence)) (, ,) (NP (NN agent)) (VP (VBD prevented) (SBAR (S (NP (NN colon) (NN cancer)) (VP (VBD decreased) (NP (NP (JJ mitotic) (NN index)) (NP (VBN altered) (NN expression) (NN c-myc)))))))) (, ,) (NP (NN p16) (NN p27)) (VP (VBG suggesting) (NP (NP (NN modulation) (NN expression) (NN gene)) (JJ potential) (NNS biomarkers) (JJ chemopreventive) (NN activity)))) |ET| |BS|155:G05.355.310 158:D23.101 203:G05.360.340.024.340.375.249.375 212:E01.370.225.500.385.500|ES| 2:1 9:1 18:1 19:1 113:1 115:1 202:1 399:1 455:1 693:1 720:1 721:1 728:1 827:1 1009:1 1124:1 1269:1 1313:1 1943:1 1944:1 1945:1 1946:1
-1 	|BT| (S (NP (JJ Hepatic) (NN loss) (NN miR-122)) (VP (VBZ predisposes) (NP (NN mouse) (JJ hepatobiliary) (NN cyst) (JJ hepatocellular) (NN carcinoma)) (PP (IN upon) (NP (NN diethylnitrosamine) (NN exposure))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 554:D02.654.442.200 555:C04.182|ES| 19:1 32:1 52:1 303:1 304:1 1789:1 1947:1 1948:1 1949:1 1950:1 1951:1 1952:1 1953:1
-1 	|BT| (S (NP (NNP Hepatitis) (NNP C) (JJ virus-induced) (NN up-regulation) (NN microRNA-155)) (VP (VBZ promotes) (NP (NN hepatocarcinogenesis) (VBG activating) (NN Wnt) (NN signaling)))) |ET| |BS|69:G02.111.087.800 184:D13.150.650.319 249:G05.355.315.800 339:G02.111.087.880 550:B04.450.410|ES| 19:1 195:1 298:1 877:1 896:1 900:1 1954:1 1955:1 1956:1 1957:1 1958:1
-1 	|BT| (S (NP (NN Hepatocarcinogenesis)) (VP (VBD induced) (NP (NN diethylnitrosamine) (JJ hepatic) (NN deletion) (NN PTEN)))) |ET| |BS|306:G05.355.600.800 554:D02.654.442.200|ES| 19:1 412:1 838:1 1059:1 1936:1 1952:1 1959:1
-1 	|BT| (NP (NP (ADJP (RB Here) (VBN studied)) (NN role) (NN HNF4alpha) (NN mechanism) (NN deregulation) (NN Cdx2) (NN colon) (NN cancer))) |ET| |BS|15:F01.829.316.616|ES| 18:1 19:1 31:1 113:1 123:1 162:1 213:1 400:1 401:1 402:1
-1 	|BT| (S (ADVP (RB Here)) (, ,) (VP (VBD investigated) (NP (NP (JJ molecular) (NN mechanism)) (VP (VBG underlying) (NP (JJ oncogenic) (NN cooperation) (NN c-Myc) (NN E2F1) (NN relationship) (JJ human) (NN liver) (NN cancer)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100|ES| 2:1 18:1 19:1 36:1 161:1 162:1 223:1 400:1 403:1 435:1 824:1 836:1 953:1 1960:1 1961:1
-1 	|BT| (S (NP (JJ Heterozygous) (NN disruption) (NN PTEN)) (VP (VBZ promotes) (NP (NP (JJ intestinal) (NN neoplasia) (NN APCmin)) (: /) (NP (CC +) (NP (NN mouse)) (: :) (NP (NN role))) (NP (NN osteopontin))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 102:C04.588.274.476.411 157:G05.380.383 350:D12.644.276.374.625|ES| 19:1 31:1 52:1 104:1 109:1 298:1 640:1 1160:1 1602:1 1936:1 1962:1 1963:1
-1 	|BT| (S (NP (NN HNF4alpha) (NN Cdx2)) (ADVP (RB also)) (VP (VBD exhibited) (NP (JJ comparable) (VBN deregulated) (NN pattern) (JJ human) (NN CRC)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 175:J01.897.280.500.269|ES| 5:1 19:1 36:1 123:1 213:1 245:1 260:1 609:1 1964:1 1965:1
-1 	|BT| (S (ADVP (RB However)) (, ,) (NP (NP (NP (NN effect) (NN HNF4alpha) (NN cancer) (NN stem) (NN cell)) (PRN (-LRB- -LRB-) (NP (NNS CSCs)) (-RRB- -RRB-))) (NP (NP (NN treatment) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN HNF4alpha)) (VP (VBD reported))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 332:A11.872.650 556:C11.768.175|ES| 2:1 10:1 14:1 18:1 19:1 75:1 94:1 123:1 303:1 304:1 433:1 441:1 546:1 993:1 1106:1 1966:1
-1 	|BT| (S (ADVP (RB However)) (, ,) (SBAR (IN whether) (S (NP (NN up-regulation) (NN DLGAP5)) (VP (VBZ contributes) (NP (NN hepatocarcinogenesis))))) (VP (VBZ remains) (ADJP (JJ unclear)))) |ET| |BS|142:I01.880.604|ES| 2:1 19:1 221:1 433:1 442:1 443:1 845:1 896:1 900:1 1191:1
-1 	|BT| (S (PP (IN In) (NP (NN aggregate))) (, ,) (VP (VBP conclude) (NP (NP (NP (NN Let-7) (NN depletion) (NN drive) (NN stem) (NN cell) (NN phenotype)) (NN development) (JJ intestinal) (NN cancer)) (, ,) (PP (ADVP (RB primarily)) (IN via) (NP (NN Hmga2)))))) |ET| |BS|66:F01.658.293 80:G05.695 101:C04.588.274.476.411 283:D12.776.260.312.937 308:A11.872 557:D02.241.081.069.600.150|ES| 2:1 18:1 19:1 35:1 94:1 109:1 181:1 236:1 244:1 596:1 1106:1 1613:1 1967:1 1968:1 1969:1 1970:1 1971:1
-1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN loss) (NN PTEN) (NN dysregulation)) (VP (VBG transforming) (NP (NP (NN growth) (NN factor) (NN beta) (NN signaling)) (VP (VBN considered) (S (NP (JJ involved) (NN rat) (NN hepatocarcinogenesis) (JJ early) (NN stage))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 69:G02.111.087.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 503:D12.644.276.374.687|ES| 2:1 19:1 32:1 102:1 185:1 195:1 244:1 774:1 849:1 900:1 1061:1 1128:1 1129:1 1202:1 1284:1 1772:1 1936:1 1972:1
-1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN MiR-7) (JJ novel) (NN miRNA) (NN tumor) (JJ suppressive) (NN function) (NN colon) (NN cancer)) (VP (VBG targeting) (NP (JJ oncogenic) (NN YY1)))) |ET| |BS|8:C04 184:D13.150.650.319 258:D12.776.260.235.875 259:D12.776.395.240.150.500 279:D27.888.569.100|ES| 2:1 7:1 18:1 19:1 33:1 113:1 244:1 616:1 840:1 879:1 891:1 953:1 1284:1 1973:1 1974:1
-1 	|BT| (NP (NP (PP (IN In) (NP (NN conclusion))) (, ,) (NP (S (VP (VBG finding) (S (VP (VBP indicate) (SBAR (S (NP (NN miR-375) (NN target) (NN AEG-1) (NN HCC)) (VP (VBZ suppresses) (NP (NN liver) (NN cancer) (NN cell) (NN growth)) (ADVP (FW vitro) (FW vivo))))))))) (, ,) (NP (NN highlight) (JJ therapeutic) (JJ potential) (NN miR-375) (NN HCC) (NN treatment))))) |ET| |BS|41:A11 45:G07.700.320.249 52:E02 104:C04.557.470.200.025.255 262:A11.436.348|ES| 2:1 18:1 19:1 94:1 102:1 160:1 216:1 244:1 378:1 441:1 541:1 546:1 686:1 827:1 836:1 927:1 1284:1 1479:1 1675:1 1975:1 1976:1
-1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN overexpression) (NN PPARgamma1) (NN gene)) (VP (VBZ exerts) (NP (NP (JJ beneficial) (NN effect)) (VP (VBG attenuating) (NP (NN atherosclerosis) (NN progression))))) (VP (VBZ stabilizes) (NP (JJ vulnerable) (NN plaque)))) |ET| |BS|6:G05.360.340.024.340 16:C23.550.291.656 511:C14.907.137.126.307 513:C14.907.137.126 558:C23.300.821|ES| 2:1 9:1 19:1 48:1 75:1 152:1 244:1 984:1 1284:1 1803:1 1804:1 1977:1 1978:1 1979:1 1980:1 1981:1
-1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NNS data)) (VP (VBP indicate) (SBAR (S (NP (NN LHX4)) (VP (MD may) (VP (VB act) (NP (JJ potential) (NN tumor) (NN suppressor) (NN hepatocarcinogenesis)) (, ,) (S (VP (VBG suggesting) (S (VP (VBG targeting) (NP (NN LHX4))))))))))) (VP (VBP downregulate) (SBAR (S (NP (NN AFP)) (VP (MD might) (NP (JJ therapeutic) (NN implication))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 81:E02.095.465.425.400.330.050.400 206:G05.360.340.024.340.375.249|ES| 2:1 7:1 19:1 85:1 244:1 246:1 491:1 508:1 541:1 616:1 700:1 793:1 798:1 827:1 900:1 1009:1 1196:1 1284:1 1479:1 1982:1
-1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN study)) (VP (VBP show) (SBAR (S (NP (NN TS) (NN gene) (NN expression) (NN pretreatment) (NN biopsy)) (VP (VBZ predicts) (NP (NN response) (JJ local) (JJ rectal) (NN cancer) (JJ neo-adjuvant) (JJ 5-FU-based) (NN chemoradiotherapy) (JJ high) (NN percentage))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 154:Z01.058.266.887 155:G05.355.310 333:D01.045 559:E01.370.225.500.384.100 560:D03.383.742.698.875.404 561:E02.186.079.500|ES| 2:1 9:1 18:1 19:1 115:1 131:1 178:1 244:1 429:1 494:1 509:1 1284:1 1751:1 1983:1 1984:1 1985:1 1986:1 1987:1 1988:1 1989:1 1990:1
-1 	|BT| (NP (NP (PP (IN In) (NP (VBN damaged) (NN tissue))) (, ,) (NP (NP (JJ combined) (NN loss) (NN RB) (NN p53)) (VBD resulted) (NP (JJ early) (NN lesion) (NN formation)) (, ,) (NP (NP (JJ aggressive) (NN tumor) (NN progression)) (, ,) (NP (NP (NN gene) (NN expression) (NN signature)) (NP (JJ histologic) (JJ characteristic) (JJ advanced) (JJ human) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 16:C23.550.291.656 20:G03.495 98:A10 104:C04.557.470.200.025.255 162:F01.145.126.125 384:G02.111.087.847.750 562:F01.510|ES| 2:1 7:1 9:1 12:1 19:1 32:1 36:1 43:1 48:1 115:1 164:1 244:1 272:1 303:1 304:1 336:1 538:1 594:1 997:1 1128:1 1131:1 1209:1 1230:1 1991:1 1992:1
-1 	|BT| (FRAG (PP (IN In) (NP (NP (NP (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (NN model) (NN colon) (NN cancer))) (, ,) (NP (NP (NN addition) (NN K-ras) (NN mutation)) (, ,) (VP (VBN shown) (S (NP (ADJP (ADJP (JJ wild-type)) (PRN (-LRB- -LRB-) (ADJP (JJ WT)) (-RRB- -RRB-))) (NN Ras)) (VP (VBD activated) (NP (NP (JJ upstream) (NN pathway)) (, ,) (S (VBG including) (, ,) (PP (FW e.g.)) (, ,) (VP (VBG signaling) (NP (NN ErbB) (NN receptor)))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 69:G02.111.087.800 132:D02.172.080 563:D08.811.913.696.620.682.725.400.009|ES| 2:1 8:1 10:1 14:1 18:1 19:1 34:1 72:1 113:1 163:1 186:1 195:1 237:1 244:1 383:1 468:1 561:1 1121:1 1775:1 1993:1 1994:1 1995:1 1996:1 1997:1 1998:1
-1 	|BT| (FRAG (PP (IN In) (NP (NN context))) (, ,) (NP (NP (NP (NN study) (NN p53)) (NP (ADVP (RB therefore)) (NP (JJ obvious) (NN implication) (JJ human) (NN health) (NN performance)))) (, ,) (NP (NP (VBN given) (JJ impaired) (JJ mitochondrial) (NN content) (NN function)) (VBN associated) (NN pathology) (JJ many) (JJ metabolic) (NN disorder)) (NP (JJ ageing) (, ,) (NN type) (CD 2) (NN diabetes)) (, ,) (NP (NN obesity) (NN cancer)) (, ,) (NP (ADJP (RB well) (VBN reduced)) (NN exercise) (NN performance)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 55:B01.050.150.900.649.801.400.112.400.400 564:C18.654.726.500 565:A11.284.430.214.190.875.564 566:G11.427.590.530.698.277 567:G05.360.340.024.340.365 568:C18.452.394.750.149 569:G07.700.320.124 570:C23.550 571:N01.400|ES| 2:1 12:1 18:1 19:1 29:1 33:1 36:1 85:1 131:1 148:1 169:1 218:1 244:1 452:1 543:1 787:1 1040:1 1794:1 1999:1 2000:1 2001:1 2002:1 2003:1 2004:1 2005:1 2006:1 2007:1 2008:1 2009:1 2010:1 2011:1
-1 	|BT| (S (PP (IN In) (NP (NN report))) (, ,) (VP (VBP show) (NP (NP (NP (NP (JJ synergistic) (NN action) (NN HBx) (NN p53) (NN mutation) (NN trigger) (JJ progressive) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN formation)) (PP (IN via) (NP (NN src) (NN activation) (NN zebrafish)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 18:G05.365.590 20:G03.495 104:C04.557.470.200.025.255 572:B01.050.150.900.493.200.244.828 573:N05.715.350.200.650|ES| 2:1 10:1 12:1 14:1 19:1 34:1 43:1 225:1 244:1 303:1 304:1 417:1 429:1 441:1 596:1 610:1 2012:1 2013:1 2014:1 2015:1 2016:1 2017:1
-1 	|BT| (S (NP (NN Inactivation) (NN APC) (NN gene)) (VP (VBN considered) (S (VP (VBG initiating) (NP (NN event) (JJ human) (JJ colorectal) (NN cancer)))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 42:G05.355.315.203.374 55:B01.050.150.900.649.801.400.112.400.400|ES| 9:1 11:1 17:1 18:1 19:1 36:1 205:1 1061:1 2018:1 2019:1
-1 	|BT| (S (NP (NN Induction) (NN p53)) (VP (VBP render) (NP (JJ ATM-deficient) (NN mouse) (JJ refractory) (NN hepatocarcinogenesis)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500|ES| 12:1 19:1 52:1 900:1 2020:1 2021:1 2022:1 2023:1
-1 	|BT| (S (NP (NNP Integrated) (JJ transcriptomic) (JJ genomic) (NN analysis)) (VP (VBN defined) (S (NP (NP (JJ distinct) (NN superenhancer) (NN CIMP)) (CC +) (NP (NN colon) (NN cancer))) (VP (VBZ regulates) (NP (NN cMYC) (NN transcription)))))) |ET| |BS|209:G02.111.087.847 268:H01.158.273.180.350 269:G05.360.340|ES| 18:1 19:1 113:1 487:1 603:1 661:1 680:1 910:1 2024:1 2025:1 2026:1 2027:1 2028:1 2029:1
-1 	|BT| (S (NP (JJ Intestinal) (NN cancer)) (VP (VBN driven) (SBAR (S (NP (ADJP (RB purely) (NN PTEN-deficiency)) (JJ transgenic) (NN mouse)) (VP (VBD developed) (NP (NP (NN CM) (JJ human) (NN CRC)) (, ,) (NP (NP (NN CM)) (VP (VBN associated) (NP (NNP PTEN) (NNP PRKCZ) (NN readout)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 66:F01.658.293 87:C18.654.521 99:B01.050.050.136.500 101:C04.588.274.476.411|ES| 2:1 18:1 19:1 36:1 52:1 169:1 204:1 245:1 285:1 920:1 1165:1 1936:1 2030:1 2031:1 2032:1 2033:1 2034:1
-1 	|BT| (S (NP (JJ Isogenic) (JJ LKB1-knockdown) (NN breast) (NN cancer) (NN cell) (NN line) (NN pair)) (VP (VBD developed))) |ET| |BS|94:A11.251.210|ES| 18:1 19:1 23:1 94:1 264:1 1165:1 2035:1 2036:1 2037:1
-1 	|BT| (S (NP (NN ITF-2)) (VP (VP (VBD disrupted) (PP (IN via) (NP (JJ allelic) (NN loss) (NN chromosome) (NN 18q21)))) (, ,) (SBAR (S (NP (NN ITF-2B) (NN expression)) (VP (VBD lost) (NP (JJ adenoma-carcinoma) (NN transition))))))) |ET| |BS|17:C04.557.470.035 289:A11.284.187 290:G05.365.590.029.530 317:C04.557.470.200.430|ES| 2:1 19:1 32:1 115:1 552:1 596:1 1005:1 1475:1 2038:1 2039:1 2040:1 2041:1 2042:1 2043:1
-1 	|BT| (S (NP (JJ K-ras) (NN mutation)) (VP (VBP occur) (ADVP (RB frequently)) (S (NP (NN colon) (NN cancer)) (VP (VBP contribute) (NP (JJ autonomous) (NN growth)))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 45:G07.700.320.249|ES| 18:1 19:1 34:1 102:1 113:1 450:1 698:1 1121:1 2044:1 2045:1
-1 	|BT| (NP (NP (JJ Many) (JJ etiological) (NN factor)) (, ,) (PP (VBG including) (NP (NP (NP (NP (NN hepatitis) (NN B) (NN virus) (NN X) (NN antigen)) (PRN (-LRB- -LRB-) (NP (NN HBx)) (-RRB- -RRB-))) (NN p53) (NN mutation)) (, ,) (NP (VBN implicated) (NN hepatocarcinogenesis))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 18:G05.365.590 73:N05.715.350.200|ES| 2:1 10:1 12:1 14:1 19:1 34:1 185:1 561:1 763:1 900:1 929:1 977:1 1030:1 1422:1 2014:1 2046:1 2047:1 2048:1
-1 	|BT| (S (NP (NNS Mice)) (NP (JJ heterozygous) (JJ dominant) (NN Min) (NN mutation) (NN Apc) (NN gene)) (VP (VBP develop) (NP (JJ multiple) (JJ intestinal) (NN neoplasia)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 21:G05.360.340.024.340.375.249.050 102:C04.588.274.476.411 157:G05.380.383|ES| 9:1 19:1 34:1 109:1 280:1 583:1 640:1 648:1 649:1 650:1 786:1 2049:1
-1 	|BT| (NP (NP (S (NP (NP (NNS Mice)) (VP (VBG lacking) (NP (NP (NN methionine) (NN adenosyltransferase) (NN 1A)) (PRN (-LRB- -LRB-) (NP (NN MAT1A)) (-RRB- -RRB-))))) (VP (VBD reduced) (NP (NN PHB1) (NN expression)))) (, ,) (JJ impaired) (JJ mitochondrial) (NN function)) (, ,) (VP (ADVP (RB spontaneously)) (VB develop) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 574:D08.811.913.225.650|ES| 2:1 10:1 14:1 19:1 33:1 115:1 303:1 304:1 376:1 441:1 452:1 583:1 648:1 1506:1 1792:1 2003:1 2004:1 2050:1 2051:1 2052:1 2053:1
-1 	|BT| (S (NP (NN MicroRNA) (NNP 301A)) (VP (VBZ Promotes) (NP (NP (JJ Intestinal) (NN Inflammation) (NNP Colitis-Associated) (NNP Cancer) (NNP Development)) (VP (VBG Inhibiting) (NP (NN BTG1)))))) |ET| |BS|47:A03.556.124 53:C06.405.205.265 122:C14.280.383 184:D13.150.650.319 525:C23.550.470|ES| 19:1 204:1 1919:1 2054:1 2055:1 2056:1 2057:1 2058:1 2059:1 2060:1 2061:1
-1 	|BT| (S (NP (NN MicroRNA-122)) (VP (VBZ inhibits) (SBAR (S (NP (JJ tumorigenic) (NN property) (JJ hepatocellular) (NN carcinoma) (NN cell)) (VP (VBZ sensitizes) (NP (NN cell) (NN sorafenib))))))) |ET| |BS|41:A11 104:C04.557.470.200.025.255 122:C14.280.383 184:D13.150.650.319 575:V02.050|ES| 19:1 94:1 303:1 304:1 615:1 841:1 1797:1 1809:1 2062:1 2063:1
-1 	|BT| (S (NP (NN microRNA-146a)) (VP (VBZ inhibits) (NP (NP (NN cancer) (NN metastasis)) (VP (VBG downregulating) (NP (NN VEGF) (JJ dual) (NN pathway) (JJ hepatocellular) (NN carcinoma)))))) |ET| |BS|104:C04.557.470.200.025.255 113:C04.697.650 122:C14.280.383 184:D13.150.650.319|ES| 18:1 19:1 303:1 304:1 383:1 615:1 806:1 2064:1 2065:1 2066:1 2067:1
-1 	|BT| (NP (NP (NP (NN MicroRNA-21) (JJ potential) (NN link) (JJ non-alcoholic) (NN fatty) (NN liver) (NN disease) (JJ hepatocellular) (NN carcinoma)) (PP (IN via) (NP (NN modulation) (NN HBP1-p53-Srebp1c) (NN pathway))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 104:C04.557.470.200.025.255 184:D13.150.650.319 576:D12.776.260.103.500.750.500 577:C06.552.241.519|ES| 19:1 303:1 304:1 383:1 596:1 827:1 836:1 998:1 1608:1 1945:1 2068:1 2069:1 2070:1 2071:1
-1 	|BT| (S (NP (NN MicroRNA-221)) (VP (VBZ governs) (S (NP (NN tumor) (NN suppressor) (NN HDAC6)) (VP (VB potentiate) (NP (JJ malignant) (NN progression) (NN liver) (NN cancer)))))) |ET| |BS|16:C23.550.291.656 30:Z01.058.290.190.800 31:D08.811.520.224.800 184:D13.150.650.319 206:G05.360.340.024.340.375.249 231:C04.557.465.625.600.380.590|ES| 7:1 18:1 19:1 48:1 700:1 802:1 836:1 2072:1 2073:1 2074:1 2075:1
-1 	|BT| (S (NP (NN MicroRNA-375) (NN target) (NN AEG-1) (JJ hepatocellular) (NN carcinoma)) (VP (VBZ suppresses) (NP (NN liver) (NN cancer) (NN cell) (NN growth)) (ADVP (FW vitro) (FW vivo)))) |ET| |BS|41:A11 45:G07.700.320.249 104:C04.557.470.200.025.255 184:D13.150.650.319 262:A11.436.348|ES| 18:1 19:1 94:1 102:1 160:1 216:1 303:1 304:1 378:1 686:1 836:1 1976:1 2076:1
-1 	|BT| (S (NP (NN MicroRNA-608)) (VP (VBZ inhibits) (NP (NN proliferation) (NN bladder) (NN cancer)) (PP (IN via) (NP (NP (NN AKT/FOXO3a)) (NN signaling) (NN pathway))))) |ET| |BS|69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 184:D13.150.650.319 378:D08.811.913.696.620.682.700.755|ES| 18:1 19:1 195:1 299:1 383:1 564:1 596:1 615:1 2077:1 2078:1
-1 	|BT| (S (NP (NN MicroRNA-7)) (VP (VBZ inhibits) (NP (NP (NN tumor) (NN growth) (NN metastasis)) (VP (VBG targeting) (NP (NN phosphoinositide) (NN 3-kinase/Akt) (NN pathway) (JJ hepatocellular) (NN carcinoma)))))) |ET| |BS|8:C04 45:G07.700.320.249 104:C04.557.470.200.025.255 113:C04.697.650 122:C14.280.383 184:D13.150.650.319 378:D08.811.913.696.620.682.700.755 578:D08.811.913.696.620.550|ES| 7:1 19:1 102:1 303:1 304:1 383:1 615:1 616:1 806:1 2079:1 2080:1 2081:1
-1 	|BT| (NP (NP (NN Microsatellite) (NN instability) (NN tool) (NN classification) (JJ gastric) (NN cancer))) |ET| |BS|395:L01.100 538:C23.550.362.590|ES| 18:1 19:1 86:1 831:1 1299:1 1338:1 2082:1
-1 	|BT| (S (NP (JJ Microsomal) (NN prostaglandin) (NN E) (NN synthase-1)) (VP (VBN involved) (NP (JJ multiple) (NN step) (NN colon) (NN carcinogenesis)))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356|ES| 19:1 113:1 207:1 649:1 774:1 2083:1 2084:1 2085:1 2086:1 2087:1
-1 	|BT| (S (NP (JJ Microsomal) (NN prostaglandin) (NN E) (NN synthase-1)) (VP (VBZ promotes) (NP (NN hepatocarcinogenesis) (NN activation) (JJ novel) (NN EGR1/beta-catenin) (NN signaling) (NN axis)))) |ET| |BS|23:D12.776.091.249 69:G02.111.087.800 259:D12.776.395.240.150.500 579:A02.835.232.834.151.383 580:D12.776.260.158.500|ES| 19:1 195:1 225:1 298:1 891:1 900:1 2083:1 2084:1 2085:1 2086:1 2088:1 2089:1
-1 	|BT| (S (NP (NN MiR-122)) (VP (VBZ inhibits) (NP (NP (NN cell) (NN proliferation) (NN tumorigenesis) (NN breast) (NN cancer)) (VP (VBG targeting) (NP (NN IGF1R)))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 122:C14.280.383 183:G04.299.233.750|ES| 18:1 19:1 23:1 78:1 94:1 299:1 615:1 616:1 2090:1 2091:1
-1 	|BT| (S (NP (NN MiR-145)) (VP (VBZ modulates) (NP (JJ multiple) (NN component) (JJ insulin-like) (NN growth) (NN factor) (NN pathway) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|104:C04.557.470.200.025.255 581:D12.644.276.937|ES| 19:1 102:1 185:1 303:1 304:1 383:1 606:1 649:1 1021:1 2092:1 2093:1
-1 	|BT| (S (NP (NN miR-185)) (VP (VBZ inhibits) (NP (NP (JJ hepatocellular) (NN carcinoma) (NN growth)) (VP (VBG targeting) (NP (NN DNMT1/PTEN/Akt) (NN pathway)))))) |ET| |BS|45:G07.700.320.249 104:C04.557.470.200.025.255 122:C14.280.383 378:D08.811.913.696.620.682.700.755|ES| 19:1 102:1 303:1 304:1 383:1 615:1 616:1 2094:1 2095:1
-1 	|BT| (S (NP (NN miR-221)) (VP (VBZ Mediates) (NP (NNP Chemoresistance) (NNP Esophageal) (NNP Adenocarcinoma) (NNP Direct) (NN Targeting) (NN DKK2) (NN Expression)))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700|ES| 19:1 140:1 316:1 1215:1 2096:1 2097:1 2098:1 2099:1 2100:1 2101:1
-1 	|BT| (S (NP (NN miR-490-3p)) (VP (VBD exerted) (NP (NP (NN growth)) (: -) (NP (NP (JJ metastasis-suppressive) (NN effect) (JJ gastric) (NN cancer) (NN cell)) (VP (ADVP (RB directly)) (VBG targeting) (NP (NP (NN SMARCD1)) (, ,) (NP (NP (NN SWItch/Sucrose) (NN NonFermentable)) (PRN (-LRB- -LRB-) (NP (NN SWI/SNF)) (-RRB- -RRB-))) (NP (NN chromatin) (NN remodeling) (NN complex) (NN subunit)))))))) |ET| |BS|41:A11 45:G07.700.320.249 113:C04.697.650 582:D09.698.629.305.770 583:D12.776.813|ES| 2:1 10:1 14:1 18:1 19:1 75:1 86:1 94:1 608:1 616:1 621:1 695:1 1346:1 2102:1 2103:1 2104:1 2105:1 2106:1 2107:1 2108:1 2109:1 2110:1
-1 	|BT| (S (NP (NN miRNA-548p)) (VP (VBZ suppresses) (NP (NP (NN hepatitis) (NN B) (NN virus) (NN X) (NN protein)) (VP (VBN associated) (NP (NP (JJ hepatocellular) (NN carcinoma)) (VP (VBG downregulating) (NP (NN oncoprotein) (NN hepatitis) (NN B) (JJ x-interacting) (NN protein)))))))) |ET| |BS|104:C04.557.470.200.025.255 184:D13.150.650.319 584:D12.776.624.664|ES| 4:1 19:1 169:1 303:1 304:1 686:1 763:1 929:1 1422:1 2048:1 2065:1 2111:1 2112:1 2113:1
-1 	|BT| (FRAG (PP (JJ Molecular) (S (VP (VBG targeting) (NP (NP (NP (NN GSK3beta) (NN overexpression) (NN GSK3beta) (JJ dominant-negative) (NN mutant)) (, ,) (NP (JJ acute-silencing) (NN GSK3beta) (NN RNA) (NN interference)) (, ,)) (VBN reproduced) (NN induction)) (NP (ADJP (RB transcriptionally) (JJ active)) (NP (NN p53) (JJ colorectal) (NN cancer) (NN cell))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 38:Z01.058.290.120.180 40:Z01.542.248.700 41:A11 156:G05.355.315.203.374.790|ES| 2:1 12:1 17:1 18:1 19:1 94:1 152:1 197:1 515:1 516:1 616:1 736:1 811:1 1854:1 1894:1 2114:1 2115:1 2116:1 2117:1
-1 	|BT| (S (S (NP (JJS Most) (JJ human) (JJ colorectal) (NN cancer)) (VP (VB arise) (NP (NN accumulation) (NN series) (JJ genetic) (NN alteration) (NN point) (NN mutation)) (PP (IN within) (NP (JJ Ki-ras) (NN p53) (NN gene))))) (, ,) (NP (NN chemical) (NN carcinogen)) (VP (MD may) (VP (VBN implicated) (NP (NN event) (ADJP (RB still) (JJ unidentified)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100 438:G05.365.590.675|ES| 2:1 9:1 12:1 17:1 18:1 19:1 34:1 36:1 205:1 491:1 776:1 864:1 951:1 977:1 1807:1 2118:1 2119:1 2120:1 2121:1 2122:1 2123:1 2124:1 2125:1 2126:1
-1 	|BT| (S (S (NP (NN Mouse) (NN strain)) (VP (VBD disrupted) (S (NP (NP (NN sPLA)) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (NN gene) (JJ susceptible) (NN Min) (NN phenotype)) (VP (VBP develop) (NP (JJ numerous) (JJ intestinal) (NN polyp))))) (, ,)) (IN whereas) (S (NP (NP (NN mouse) (JJ normal) (NN sPLA)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (VP (VBP develop) (NP (JJ limited) (NN number) (NN polyp))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 80:G05.695 192:D08.811.277.352.100.680.750.937.750 193:C23.300.825.411 444:C23.300.825|ES| 2:1 9:1 10:1 14:1 19:1 52:1 109:1 118:1 148:1 236:1 372:1 646:1 647:1 648:1 650:1 899:1 2039:1 2127:1 2128:1 2129:1 2130:1 2131:1
-1 	|BT| (NP (NP (NNS Mutations) (NP (NP (NN APC) (NN gene) (JJ responsible) (JJ familial) (JJ adenomatous) (NN polyposis)) (PRN (-LRB- -LRB-) (NP (NN FAP)) (-RRB- -RRB-))) (NN majority) (JJ sporadic) (JJ colorectal) (NN cancer))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 18:G05.365.590 21:G05.360.340.024.340.375.249.050|ES| 9:1 10:1 11:1 14:1 17:1 18:1 19:1 57:1 58:1 198:1 725:1 854:1 1410:1 2132:1 2133:1
-1 	|BT| (NP (NP (NNS Mutations)) (NP (NP (NP (JJ human) (NN DNA) (NN mismatch) (NN repair)) (PRN (-LRB- -LRB-) (NP (NN MMR)) (-RRB- -RRB-))) (NP (NP (NP (NN gene) (NN MLH1) (VBN associated) (JJ hereditary) (JJ nonpolyposis) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NP (NNP Lynch) (NN syndrome)) (, ,) (NP (NN HNPCC))) (-RRB- -RRB-))) (NP (JJ significant) (NN proportion) (JJ sporadic) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 174:G02.111.087.219.220 524:C04.588.274.476.411.307.190|ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 36:1 135:1 169:1 513:1 584:1 666:1 723:1 725:1 1294:1 1410:1 1845:1 1846:1 1940:1 2134:1 2135:1 2136:1
-1 	|BT| (NP (NNS Mutations) (NP (NP (NN APC) (NN gene) (NN play) (JJ critical) (NN role)) (JJ sporadic) (JJ familial) (NN form) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 18:G05.365.590 21:G05.360.340.024.340.375.249.050 44:F01.829.263 79:I03.450.642.693 189:V02.460|ES| 9:1 11:1 17:1 18:1 19:1 31:1 238:1 630:1 725:1 825:1 854:1 1410:1
-1 	|BT| (S (NP (NN NAC1)) (VP (VBZ modulates) (NP (NP (NN sensitivity) (JJ ovarian) (NN cancer) (NN cell) (NN cisplatin)) (VP (VBG altering) (NP (JJ HMGB1-mediated) (JJ autophagic) (NN response)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 390:G04.299.139.399 498:D01.210.375 585:D12.644.276.087.371|ES| 18:1 19:1 94:1 494:1 606:1 607:1 1761:1 1763:1 2137:1 2138:1 2139:1 2140:1
-1 	|BT| (S (NP (NN Number) (NN size) (JJ intestinal) (NN tumor)) (ADVP (RB significantly)) (VP (VBD increased) (NP (NN mouse) (NN bearing) (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN PTEN) (NN mutation)))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 21:G05.360.340.024.340.375.249.050 102:C04.588.274.476.411 455:B01.050.150.900.649.147.890|ES| 7:1 10:1 11:1 14:1 19:1 34:1 47:1 52:1 57:1 58:1 59:1 109:1 124:1 1584:1 1936:1 2141:1 2142:1
-1 	|BT| (S (NP (JJ Oncogenic) (NN mutation) (NN K-ras) (NN gene)) (VP (VBP occur) (NP (NP (QP (RB approximately) (CD 50)) (NN %)) (NP (JJ human) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100|ES| 9:1 17:1 18:1 19:1 34:1 36:1 368:1 369:1 1121:1 1843:1 2044:1 2143:1
-1 	|BT| (S (NP (NP (CD One) (JJ common) (JJ rate-limiting) (NN mutation)) (JJ human) (NN CRC)) (VP (VBZ occurs) (NP (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene)))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 21:G05.360.340.024.340.375.249.050 55:B01.050.150.900.649.801.400.112.400.400 194:G05.355.044.250.750|ES| 9:1 10:1 11:1 14:1 19:1 34:1 36:1 57:1 58:1 59:1 245:1 654:1 655:1 656:1 657:1
-1 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBP suggest) (NP (JJ important) (NP (NN role) (NN beta2-AR/STAT3/miR) (CD -373) (NN signaling) (NN transformation) (JJ gastric) (NN cancer) (NN cell))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 41:A11 69:G02.111.087.800 82:D12.644.360.024.342.300|ES| 18:1 19:1 31:1 86:1 94:1 195:1 658:1 793:1 796:1 902:1 1384:1 2144:1
-1 	|BT| (S (NP (PRP$ Our) (NN finding) (NN support) (JJ mir-660) (NN act) (NN tumor) (NN suppressor) (NN miRNA)) (VP (VBP suggest) (NP (NN replacement) (JJ mir-660) (JJ new) (JJ therapeutic) (NN approach) (NN p53) (JJ wild-type) (NN lung) (NN cancer) (NN treatment)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 52:E02 81:E02.095.465.425.400.330.050.400 181:E04.936.494 184:D13.150.650.319 206:G05.360.340.024.340.375.249 275:C23.888 375:Z01.639.100|ES| 7:1 8:1 12:1 18:1 19:1 246:1 328:1 373:1 541:1 546:1 614:1 658:1 700:1 712:1 796:1 840:1 911:1 927:1 1364:1
-1 	|BT| (S (NP (PRP$ Our) (NN finding)) (VP (VBP suggest) (SBAR (S (NP (NN JNK/PTEN) (NN NF-kappaB/PTEN) (NN pathway)) (VP (VBP play) (NP (JJ critical) (NP (NN role) (JJ normal) (NP (JJ intestinal) (NN homeostasis) (NN colon) (NN carcinogenesis))))))))) |ET| |BS|15:F01.829.316.616 33:C04.697.098 46:A03.556.124.526.356 47:A03.556.124 79:I03.450.642.693 152:G07.700.345 210:D12.776.260.600|ES| 19:1 31:1 109:1 113:1 118:1 207:1 238:1 383:1 500:1 658:1 796:1 825:1 927:1 2145:1 2146:1
-1 	|BT| (S (NP (NP (PRP$ Our) (VBN integrated) (NN microRNA)) (VP (VBG profiling) (NP (NN approach)))) (VP (VBD identified) (S (NP (NN miR-195-5p)) (ADVP (RB independently)) (VP (VBN associated) (NP (NN prognosis) (NN CRC)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 163:E01.789 184:D13.150.650.319|ES| 19:1 169:1 245:1 271:1 544:1 623:1 658:1 857:1 911:1 2147:1 2148:1 2149:1
-1 	|BT| (S (NP (PRP$ Our) (JJ recent) (NN study)) (VP (VB establish) (NP (JJ oncogenic) (NN role) (NP (NP (NNP LSF) (JJ Hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 104:C04.557.470.200.025.255 279:D27.888.569.100|ES| 10:1 14:1 19:1 31:1 131:1 220:1 304:1 441:1 658:1 659:1 953:1 2150:1 2151:1
-1 	|BT| (S (NP (PRP$ Our) (JJ recent) (NN study)) (VP (VBZ indicates) (SBAR (S (NP (NNS AR)) (VP (VBZ upregulates) (NP (NP (NN expression) (NN tumor) (NN suppressor) (NN gene) (NN PTEN) (NN promoter)) (NN activation) (NN breast) (NN cancer))))))) |ET| |BS|155:G05.355.310 206:G05.360.340.024.340.375.249|ES| 7:1 9:1 18:1 19:1 23:1 83:1 115:1 131:1 225:1 628:1 658:1 659:1 700:1 1936:1 2152:1 2153:1
-1 	|BT| (S (NP (PRP$ Our) (NN study)) (VP (VBP identify) (NP (NP (NN network) (NN protein)) (, ,) (PP (VBG including) (NP (NP (NP (NN osteopontin)) (PRN (-LRB- -LRB-) (NP (NN OPN)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Matrix) (NN metalloproteinase-9)) (PRN (-LRB- -LRB-) (NP (NN MMP-9)) (-RRB- -RRB-))) (, ,) (NP (NP (NN c-Met) (NN complement) (NN factor) (NN H)) (PRN (-LRB- -LRB-) (NP (NN CFH)) (-RRB- -RRB-))) (, ,) (VP (ADVP (RB directly)) (VBN regulated) (NP (NP (NN LSF) (NN play) (JJ important) (NN role)) (JJ LSF-induced) (NN hepatocarcinogenesis)))))))) |ET| |BS|15:F01.829.316.616 79:I03.450.642.693 112:D12.776.097.820 142:I01.880.604 350:D12.644.276.374.625 586:D08.811.277.656.300.480.205.360 587:D12.776.124.486.274.920.325.200 588:I01.880.853.500.600|ES| 2:1 4:1 10:1 14:1 19:1 31:1 131:1 185:1 238:1 561:1 612:1 621:1 658:1 832:1 900:1 902:1 1160:1 1664:1 2150:1 2154:1 2155:1 2156:1 2157:1 2158:1 2159:1 2160:1 2161:1 2162:1
-1 	|BT| (S (NP (NN Overexpression) (NN miR-375) (NN liver) (NN cancer) (NN cell)) (VP (VBD decreased) (NP (NP (NN cell) (NN proliferation)) (, ,) (NP (NN clonogenicity)) (, ,) (NP (NN migration/invasion))) (ADVP (RB also)) (VP (VBD induced) (NP (NN G1) (NN arrest) (NN apoptosis))))) |ET| |BS|39:G04.299.139.160 41:A11 183:G04.299.233.750 262:A11.436.348|ES| 2:1 5:1 18:1 19:1 89:1 94:1 202:1 299:1 412:1 602:1 668:1 669:1 670:1 836:1 1975:1 2163:1
-1 	|BT| (S (NP (NN p53)) (VP (VBZ promotes) (NP (NP (JJ inflammation-associated) (NN hepatocarcinogenesis)) (VP (VBG inducing) (NP (NN HMGB1) (NN release)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 525:C23.550.470 585:D12.644.276.087.371 589:E02.204.125|ES| 12:1 19:1 298:1 900:1 1849:1 1864:1 2164:1 2165:1
-1 	|BT| (NP (NP (JJ Paired) (NN box) (NN gene) (CD 5) (JJ novel) (NN tumor) (NN suppressor) (JJ hepatocellular) (NN carcinoma) (NN interaction) (NN p53) (NN signaling) (NN pathway))) |ET| |BS|2:G05.360.340.024.340.375.249.385 6:G05.360.340.024.340 69:G02.111.087.800 104:C04.557.470.200.025.255 126:G02.111.087.800 206:G05.360.340.024.340.375.249 243:D12.776.260.645.500 259:D12.776.395.240.150.500|ES| 7:1 9:1 12:1 19:1 195:1 303:1 304:1 383:1 578:1 618:1 700:1 891:1 1918:1 2166:1
-1 	|BT| (NP (NP (NNP Parkin) (NN tumor) (NN suppressor) (NN gene) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255 206:G05.360.340.024.340.375.249|ES| 7:1 9:1 19:1 303:1 304:1 700:1 2167:1
-1 	|BT| (S (NP (NP (NNP PIRC) (NN rat)) (PRN (-LRB- -LRB-) (NP (NP (NN F344/NTac-Apc)) (PRN (-LRB- -LRB-) (NP (NN am1137)) (-RRB- -RRB-))) (-RRB- -RRB-))) (NP (VBN mutated) (NN Apc) (NN gene)) (ADVP (RB spontaneously)) (VP (VB develop) (NP (NN colon)) (NP (NN tumor)) (ADVP (RB thus)) (VP (NP (VBG mimicking) (JJ familial) (NP (NP (JJ adenomatous) (NN polyposis) (-LRB- -LRB-) (NN FAP) (-RRB- -RRB-) (JJ sporadic) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (RB closely) (JJ Apc-based) (JJ rodent) (NN model)) (S (VP (VBG developing) (NP (NP (NN tumor)) (ADJP (RB mostly) (JJ small)) (NN intestine))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 21:G05.360.340.024.340.375.249.050 51:C04.588.274.476.411.307.180 102:C04.588.274.476.411 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 333:D01.045 514:B01.050.150.900.649.865 590:B01.050.050.199.520.760.200|ES| 7:1 9:1 10:1 14:1 17:1 18:1 19:1 57:1 58:1 72:1 113:1 229:1 245:1 280:1 356:1 590:1 648:1 725:1 750:1 849:1 854:1 855:1 1334:1 1506:1 2133:1 2168:1 2169:1 2170:1 2171:1 2172:1 2173:1 2174:1
-1 	|BT| (S (NP (NP (NP (JJ Real-time) (JJ reverse) (NN transcription) (NN polymerase) (NN chain) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NN RT-PCR)) (-RRB- -RRB-))) (NN analysis)) (VP (VBD demonstrated) (NP (NP (NN up-regulation) (JJ oncogenic) (NN miR-155)) (, ,) (NP (NP (NN miR-221)) (: /) (NP (CD 222))) (, ,) (NP (NP (NN miR-21) (NN down-regulation) (JJ abundant) (JJ liver-specific) (NN miR-122)) (JJ early) (NN stage) (NN hepatocarcinogenesis))))) |ET| |BS|85:G02.111.087.225 242:A03.620 249:G05.355.315.800 272:E05.393.620.500.725 279:D27.888.569.100 339:G02.111.087.880 346:E05.393.620.500.706 591:G02.111.087.847.500|ES| 2:1 10:1 14:1 19:1 257:1 394:1 487:1 661:1 768:1 896:1 900:1 939:1 941:1 953:1 1128:1 1129:1 1148:1 1175:1 1789:1 1798:1 1799:1 1911:1 2175:1 2176:1 2177:1
-1 	|BT| (S (ADVP (RB Recently)) (, ,) (S (NP (NP (NN microRNA-122)) (PRN (-LRB- -LRB-) (NP (NN miR-122)) (-RRB- -RRB-))) (VP (VBD proved) (NP (NP (NN play) (JJ important) (NN role)) (NP (JJ hepatocellular) (NN carcinoma))))) (, ,) (NP (NP (NN function) (NN context) (NN breast) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN BC)) (-RRB- -RRB-))) (VP (VBP remain) (ADJP (JJ unknown)))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 79:I03.450.642.693 104:C04.557.470.200.025.255 184:D13.150.650.319|ES| 2:1 10:1 14:1 18:1 19:1 23:1 31:1 33:1 238:1 303:1 304:1 902:1 1789:1 1857:1 1999:1 2178:1 2179:1 2180:1 2181:1 2182:1
-1 	|BT| (S (ADVP (RB Recently)) (, ,) (NP (NP (NP (NP (NN microRNA-7)) (PRN (-LRB- -LRB-) (NP (NN miR-7)) (-RRB- -RRB-))) (NP (NP (JJ proven) (NN play) (JJ substantial) (NN role)) (NP (NN glioblastoma) (NN breast) (NN cancer)))) (, ,) (NP (NN function) (NN context) (NNP HCC))) (VP (VBP remain) (ADJP (JJ unknown)))) |ET| |BS|15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 79:I03.450.642.693 104:C04.557.470.200.025.255 184:D13.150.650.319 592:C04.557.465.625.600.380.080.335|ES| 2:1 10:1 14:1 18:1 19:1 23:1 31:1 33:1 238:1 441:1 1293:1 1999:1 2178:1 2181:1 2182:1 2183:1 2184:1 2185:1 2186:1
-1 	|BT| (S (NP (NN Role) (NN microRNA-155) (JJ early) (NN stage) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (JJ choline-deficient) (NN amino) (JJ acid-defined) (NN diet) (NN C57BL/6) (NN mouse)))) |ET| |BS|15:F01.829.316.616 184:D13.150.650.319 593:B01.050.050.199.520.520.420 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125|ES| 19:1 52:1 412:1 900:1 1128:1 1129:1 1957:1 2187:1 2188:1 2189:1 2190:1 2191:1 2192:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN ATA)) (VP (MD may) (NP (JJ broad) (NN utility) (NN treatment) (JJ HER2-overexpressed) (NN breast) (NN cancer))))))) |ET| |BS|52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 520:C10.228.140.252.190.530.060|ES| 2:1 18:1 19:1 23:1 491:1 546:1 793:1 796:1 1537:1 1538:1 1820:1 2193:1 2194:1 2195:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NN study) (VP (VBP indicate) (SBAR (S (NP (VBN upregulated) (NN BYSL) (NN expression)) (VP (VBP play) (NP (NN role) (NN hepatocarcinogenesis))))))) |ET| |BS|15:F01.829.316.616 79:I03.450.642.693|ES| 2:1 19:1 31:1 115:1 125:1 131:1 238:1 900:1 1479:1 1537:1 1538:1 2196:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (VP (VB identify) (SBAR (S (NP (NN downregulation) (NN miR-497) (JJ important) (NN mechanism) (NN upregulation) (NN IGF1-R) (NN CRC) (NN cell)) (VP (VBZ contributes) (NP (NN malignancy) (NN CRC)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 85:G02.111.087.225 249:G05.355.315.800 339:G02.111.087.880 375:Z01.639.100 598:D12.644.276.937.400 599:M01.526.799.500|ES| 2:1 19:1 49:1 94:1 101:1 162:1 245:1 595:1 832:1 845:1 902:1 1126:1 1537:1 1538:1 2197:1 2198:1
-1 	|BT| (NP (NP (NP (DT The) (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene) (NN product)) (NP (VBN mutated) (JJ vast) (NN majority) (JJ human) (JJ colorectal) (NN cancer)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 219:G05.360.340.024.340.375.249.320 220:D05.500.117.249|ES| 9:1 10:1 11:1 14:1 17:1 18:1 19:1 36:1 57:1 58:1 59:1 198:1 229:1 675:1 691:1 752:1
-1 	|BT| (NP (NP (NP (DT The) (NN APC) (NN gene) (NN play) (JJ major) (NN role)) (NP (JJ human) (NN colon) (NN carcinogenesis)))) |ET| |BS|15:F01.829.316.616 21:G05.360.340.024.340.375.249.050 33:C04.697.098 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693|ES| 9:1 11:1 19:1 31:1 36:1 113:1 207:1 238:1 462:1 691:1
-1 	|BT| (NP (NP (NP (DT The) (NN B-cell) (NN tumor) (NN promoter)) (SBAR (S (NP (NN Bcl-3)) (VP (VBZ suppresses) (NP (JJ inflammation-associated) (NN colon) (NN tumorigenesis) (JJ epithelial) (NN cell))))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 53:C06.405.205.265 75:A11.436 310:A11.063.438 600:D27.888.569.100|ES| 7:1 19:1 78:1 83:1 94:1 113:1 127:1 404:1 686:1 691:1 1849:1 2199:1
-1 	|BT| (S (NP (DT The) (NP (NN c-myc) (NN oncogene) (NN play) (JJ important) (NN role)) (NN tumorigenesis)) (ADVP (RB frequently)) (VP (VBD deregulated) (NP (NP (JJ many) (JJ human) (NN cancer)) (, ,) (PP (VBG including) (NP (JJ gastrointestinal) (NN cancer)))))) |ET| |BS|9:G05.360.340.024.340.375.500 12:Z01.542.049 15:F01.829.316.616 32:C04.697.098.500 33:C04.697.098 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693|ES| 2:1 18:1 19:1 24:1 31:1 36:1 78:1 183:1 238:1 455:1 561:1 691:1 698:1 902:1 1040:1 1965:1
-1 	|BT| (NP (NP (DT The) (NN ECM-modulator) (NN inter)) (: -) (S (NP (NP (NN alpha-trypsin) (NN inhibitor) (JJ heavy) (NN chain) (NN family) (NN member)) (CD five) (-LRB- -LRB-) (NN ITIH5) (-RRB- -RRB-)) (ADVP (RB recently)) (VP (VBD identified) (NP (NP (NN tumor) (NN suppressor)) (VP (ADVP (RB potentially)) (VP (VBN involved) (NP (NP (VBG impairing) (NN breast) (NN cancer) (NN progression) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (S (NP (NN function)) (ADJP (ADVP (RB still)) (JJ elusive))))))))))) |ET| |BS|16:C23.550.291.656 44:F01.829.263 206:G05.360.340.024.340.375.249 223:A11.284.295.310|ES| 7:1 10:1 14:1 18:1 19:1 23:1 33:1 48:1 97:1 161:1 162:1 380:1 435:1 623:1 691:1 700:1 764:1 765:1 766:1 767:1 768:1 769:1 770:1 771:1 772:1 773:1 774:1 775:1 776:1 777:1
-1 	|BT| (S (NP (DT The) (NN finding) (JJ parkin-deficient) (NN mouse) (JJ susceptible) (NN hepatocarcinogenesis)) (VP (VBN provided) (VP (JJ first) (NP (NN evidence) (VP (VBG showing) (NP (JJ parkin) (ADVP (RB indeed)) (NP (NN tumor) (NN suppressor) (NN gene)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 206:G05.360.340.024.340.375.249 275:C23.888|ES| 7:1 9:1 19:1 38:1 52:1 691:1 700:1 816:1 899:1 900:1 927:1 1155:1 2200:1 2201:1 2202:1 2203:1
-1 	|BT| (S (NP (DT The) (NN finding)) (VP (MD may) (VP (VB provide) (NP (NP (NN basis) (NN understanding) (JJR greater) (NN predisposition) (JJ intestinal) (NN cancer) (NN Mlh1)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-))) (NP (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 101:C04.588.274.476.411 239:F02.463.188.357 401:C23.550.291.687|ES| 10:1 14:1 18:1 19:1 45:1 52:1 109:1 491:1 586:1 691:1 711:1 905:1 927:1 1140:1 1768:1 2204:1
-1 	|BT| (NP (NP (NP (DT The) (NP (NN ITF-2) (NN gene))) (JJ located) (JJ chromosomal) (NN region) (NN 18q21)) (: ;) (S (NP (JJ allelic) (NN loss) (NN locus)) (VP (VBZ occurs) (NP (ADJP (CD 70) (NN %)) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 6:G05.360.340.024.340 289:A11.284.187 290:G05.365.590.029.530 292:Z01|ES| 9:1 17:1 18:1 19:1 32:1 217:1 369:1 377:1 657:1 667:1 691:1 1002:1 1475:1 2038:1 2040:1 2205:1 2206:1
-1 	|BT| (NP (NP (DT The) (NN K-sam) (NN gene)) (, ,) (VP (ADVP (RB originally)) (VBN isolated) (NP (NP (VBN amplified) (NN gene) (NN stomach) (NN cancer) (NN cell) (NN line) (NN KATO-III)) (, ,) (VP (VBN characterized) (S (NP (NP (NP (JJ preferential) (NN amplification) (JJ undifferentiated) (NN type)) (PRN (-LRB- -LRB-) (NP (JJ diffuse) (NN type)) (-RRB- -RRB-))) (NN stomach) (NN cancer)) (VP (VBZ encodes) (NP (CD one) (NN receptor) (JJ heparin-binding) (NN growth) (NN factor) (NN fibroblast) (NN growth) (NN factor)))))))) |ET| |BS|6:G05.360.340.024.340 94:A11.251.210 232:D02.886.030.676.180 601:D12.644.276.624 602:D09.698.373.400|ES| 2:1 9:1 10:1 14:1 18:1 19:1 94:1 102:1 185:1 186:1 264:1 543:1 653:1 691:1 801:1 803:1 804:1 921:1 985:1 1010:1 1653:1 2207:1 2208:1 2209:1 2210:1 2211:1 2212:1 2213:1
-1 	|BT| (UCP (S (NP (DT The) (NN miR-122) (JJ regulatory) (NN circuitry) (NN implication) (NN hepatocarcinogenesis)) (VP (VBN identified) (S (VP (VBG using) (NP (NN liver) (JJ different) (NN development) (NN stage)))))) (, ,) (NP (NP (NP (NP (JJ human) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NP (NN tissue) (NN cell) (NN line)) (, ,) (NP (NP (NN aflatoxin) (NN B)) (-LRB- -LRB-) (CD 1) (-RRB- -RRB-) (-LRB- -LRB-) (NN AFB) (LST (-LRB- -LRB-) (CD 1) (-RRB- -RRB-) (-RRB- -RRB-)))) (: -) (NP (VBN transformed) (NN cell)))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 98:A10 104:C04.557.470.200.025.255 242:A03.620 603:D03.383.663.283.119.075|ES| 2:1 10:1 14:1 19:1 35:1 36:1 85:1 94:1 98:1 264:1 272:1 303:1 304:1 350:1 414:1 441:1 623:1 691:1 763:1 836:1 900:1 1129:1 1789:1 1817:1 1818:1 2214:1 2215:1 2216:1
-1 	|BT| (S (NP (DT The) (NN orphan) (NN cotransport) (NN protein)) (VP (VBD expressed) (NP (NP (NP (NN SLC5A8) (NN gene) (VBN shown) (NN play) (NN role)) (NP (VBG controlling) (NN growth) (NN colon) (NN cancer))) (, ,) (NP (NN silencing) (NP (NN gene) (JJ common) (NP (JJ early) (NN event) (JJ human) (NN colon) (NN neoplasia))))))) |ET| |BS|6:G05.360.340.024.340 7:D12.776 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 42:G05.355.315.203.374 45:G07.700.320.249 51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693 604:M01.108|ES| 2:1 4:1 6:1 9:1 18:1 19:1 31:1 36:1 100:1 102:1 113:1 205:1 237:1 238:1 640:1 655:1 691:1 1128:1 2217:1 2218:1 2219:1 2220:1
-1 	|BT| (NP (NP (NP (DT The) (JJ potential) (NN utility) (NN acetyltanshinone) (NN IIA) (NN treatment) (JJ HER2-overexpressed) (NN breast) (NN cancer)) (: :) (NP (NP (NN Induction) (NN cancer) (NN cell) (NN death)) (VP (VBG targeting) (NP (JJ apoptotic) (JJ metabolic) (NN signaling) (NN pathway)))))) |ET| |BS|33:C04.697.098 39:G04.299.139.160 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 69:G02.111.087.800 126:G02.111.087.800 134:G04.299.139 605:G03.495.553|ES| 18:1 19:1 23:1 94:1 104:1 195:1 383:1 411:1 546:1 616:1 691:1 827:1 2006:1 2020:1 2194:1 2195:1 2221:1 2222:1 2223:1
-1 	|BT| (S (NP (NP (DT The) (NN proliferation)) (NP (JJ certain) (NP (JJ human) (JJ HER2-positive) (NN breast) (NN cancer) (NN line)))) (ADVP (RB also)) (VP (VBZ requires) (SBAR (S (NP (NP (NN HSF1)) (, ,) (NP (NN knockdown))) (VP (VBD led) (NP (NP (NN upregulation) (NN p21)) (CC and/or) (NP (NN decrease) (NN survivin))) (, ,) (S (VP (VBG precipitating) (NP (NN growth) (NN arrest))))))))) |ET| |BS|45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 86:D01.268.556.435 249:G05.355.315.800 339:G02.111.087.880|ES| 2:1 5:1 18:1 19:1 23:1 36:1 102:1 149:1 264:1 295:1 299:1 464:1 602:1 691:1 1126:1 1135:1 2224:1 2225:1 2226:1 2227:1 2228:1 2229:1 2230:1
-1 	|BT| (S (NP (DT The) (NN result)) (VP (VBP suggest) (SBAR (S (NP (NN MTHFR) (NN genotype) (JJ relevant) (JJ independent) (NN factor) (NN patient) (NN outcome) (JJ 5FU-based) (NN treatment)) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 52:E02 333:D01.045 396:G05.380 560:D03.383.742.698.875.404 606:D08.811.682.662.290|ES| 17:1 18:1 19:1 101:1 120:1 185:1 546:1 547:1 691:1 796:1 865:1 883:1 997:1 1329:1 2231:1 2232:1
-1 	|BT| (S (NP (DT The) (NN Tg737) (NN gene)) (VP (VBD found) (NP (NP (JJ altered) (ADJP (QP (RB approximately) (CD 40)) (NN %)) (JJ rodent) (JJ chemically-induced) (NN liver) (NN tumor)) (, ,) (NP (NP (CD 40) (NN %)) (JJ human) (NN liver) (NN tumor)) (, ,) (NP (NN liver)) (, ,) (NP (NN kidney) (JJ pancreatic) (JJ human) (NN tumor) (NN cell) (NN line))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 242:A03.620 485:A05.810.453 514:B01.050.150.900.649.865 515:C04.588.274.623 607:A11.251.210.190 608:A03.734|ES| 2:1 7:1 9:1 19:1 36:1 37:1 94:1 264:1 369:1 467:1 582:1 691:1 693:1 836:1 1717:1 1805:1 1843:1 2173:1 2233:1
-1 	|BT| (NP (NP (NP (DT The) (NN transcription) (NN factor) (NNP LSF)) (: :) (NP (JJ novel) (NN oncogene) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|9:G05.360.340.024.340.375.500 104:C04.557.470.200.025.255 166:D12.776.930 259:D12.776.395.240.150.500|ES| 19:1 24:1 104:1 185:1 303:1 304:1 487:1 691:1 891:1 2150:1
-1 	|BT| (S (ADVP (RB Therefore)) (NP (NN bile) (NN duct) (NN cancer) (NN patient)) (VP (MD may) (NP (VBN treated) (NN miR-34a) (NN inhibitor) (NN Per1) (NN stimulator) (NN future)))) |ET| |BS|50:M01.643 52:E02 354:I01.320|ES| 18:1 19:1 120:1 380:1 491:1 1099:1 1190:1 1620:1 1621:1 1622:1 1623:1 1624:1 1625:1
-1 	|BT| (S (ADVP (RB Therefore)) (, ,) (VP (VBP conclude) (SBAR (S (NP (NP (NN miR-141) (NN target) (NN MAP4K4)) (, ,) (VP (VBP act) (NP (NN tumor) (NN suppressor) (JJ pancreatic) (NN cancer) (NN cell))) (, ,)) (VP (MD may) (VP (VB serve) (NP (ADJP (ADJP (JJ novel)) (ADJP (JJ therapeutic))) (NN agent) (JJ miRNA-based) (JJ pancreatic) (NN cancer) (NN therapy)))))))) |ET| |BS|41:A11 52:E02 81:E02.095.465.425.400.330.050.400 184:D13.150.650.319 206:G05.360.340.024.340.375.249 259:D12.776.395.240.150.500 333:D01.045 557:D02.241.081.069.600.150|ES| 2:1 7:1 18:1 19:1 94:1 130:1 160:1 246:1 463:1 465:1 467:1 491:1 532:1 541:1 700:1 728:1 891:1 1620:1 1968:1 2234:1
-1 	|BT| (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN HNF4alpha)) (VP (VBZ maintains) (NP (NP (NN hepatocyte) (NN differentiation) (JJ adult) (JJ healthy) (NN liver)) (, ,) (S (NP (NN loss)) (VP (MD may) (ADVP (RB directly)) (VP (VB contribute) (NP (JJ hepatocellular) (NN carcinoma) (NN development))) (, ,) (S (VP (ADVP (RB thus)) (VBG indicating) (NP (NN factor) (JJ possible) (NN liver) (NN tumor) (NN suppressor) (NN gene)))))))))))) |ET| |BS|74:G04.299.151 104:C04.557.470.200.025.255 119:M01.060.116 188:N02.628 206:G05.360.340.024.340.375.249 242:A03.620 262:A11.436.348 571:N01.400|ES| 2:1 7:1 9:1 19:1 32:1 35:1 123:1 185:1 215:1 303:1 304:1 355:1 450:1 491:1 621:1 631:1 700:1 792:1 793:1 796:1 836:1 1334:1 1359:1 1909:1 2235:1 2236:1
-1 	|BT| (S (NP (DT These) (VBG finding) (NP (VBN suggested) (NN Notch1) (NN signaling))) (VP (VBP play) (NP (NP (NP (JJ important) (NN role) (NN maintenance) (NN cancer)) (JJ stem-like) (NN phenotype) (JJ diffuse) (NN type) (JJ gastric) (NN cancer) (NN RBP-Jkappa) (JJ dependent) (NN pathway)) (VP (VBG inhibiting) (NP (NN Notch1) (NN signaling)))) (VP (MD could) (NP (JJ effective) (NN therapy) (NN CD133) (JJ positive) (JJ diffuse) (NN type) (JJ gastric) (NN cancer))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 52:E02 69:G02.111.087.800 79:I03.450.642.693 80:G05.695 122:C14.280.383 188:N02.628 309:A18.024.937|ES| 18:1 19:1 31:1 86:1 130:1 195:1 233:1 236:1 238:1 321:1 383:1 543:1 651:1 652:1 653:1 792:1 880:1 902:1 908:1 925:1 927:1 1062:1 1063:1 1638:1 1639:1
-1 	|BT| (S (NP (DT These) (NN study)) (VP (VB establish) (NP (NP (JJ key) (NN role) (NN LSF) (NN hepatocarcinogenesis) (NN usher) (JJ novel) (JJ therapeutic) (NN avenue)) (NP (NNP HCC))) (, ,) (NP (RB invariably) (JJ fatal) (NN disease)))) |ET| |BS|15:F01.829.316.616 52:E02 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500 288:C23.550.288|ES| 2:1 19:1 31:1 131:1 159:1 220:1 441:1 541:1 792:1 891:1 900:1 998:1 1655:1 2150:1 2237:1 2238:1 2239:1
-1 	|BT| (S (NP (NP (DT This) (JJ first) (NN study)) (VP (VBG showing) (NP (NN miR-205)))) (VP (VBZ inhibits) (NP (JJ proto-oncogenic) (NNS SFKs)) (, ,) (S (VP (VBG indicating) (NP (JJ therapeutic) (JJ potential) (NN miR-205) (NN treatment) (JJ renal) (NN cancer)))))) |ET| |BS|52:E02 122:C14.280.383 279:D27.888.569.100|ES| 2:1 18:1 19:1 131:1 541:1 546:1 615:1 807:1 816:1 827:1 922:1 2201:1 2236:1 2240:1 2241:1 2242:1
-1 	|BT| (S (NP (DT This)) (VP (VBD led) (SBAR (S (NP (NN u)) (VP (VBP investigate) (SBAR (S (NP (NP (JJ antitumor) (NN growth)) (NP (JJ antimetastatic) (NN activity) (NN alpha-mangostin) (JJ immunocompetent) (NN xenograft) (NN model) (NN mouse) (JJ metastatic) (JJ mammary) (NN cancer) (NN p53) (NN mutation))) (VP (VBZ induces) (NP (NP (JJ metastatic) (NN spectrum)) (NP (JJ similar) (VBN seen) (JJ human) (NN breast) (NN cancer))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 10:A01.236 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 86:D01.268.556.435 92:E04.936.764 93:A01.941.875 113:C04.697.650 213:F02.830.816.964 609:A01.236.249 610:G12.460|ES| 12:1 18:1 19:1 23:1 34:1 36:1 52:1 72:1 102:1 214:1 265:1 332:1 337:1 399:1 459:1 724:1 807:1 2228:1 2243:1 2244:1 2245:1 2246:1 2247:1 2248:1 2249:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN inactivation) (NN TGF-beta) (NN signaling) (NN loss) (NN PTEN)) (VP (VBP cooperate) (NP (NP (NN drive) (JJ intestinal) (NN cancer) (NN formation) (NN progression)) (VP (VBG suppressing) (NP (NN cell) (NN cycle) (NN inhibitor)))))) |ET| |BS|16:C23.550.291.656 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 66:F01.658.293 69:G02.111.087.800 101:C04.588.274.476.411 353:G04.299.134 503:D12.644.276.374.687|ES| 2:1 18:1 19:1 32:1 43:1 48:1 94:1 109:1 181:1 195:1 380:1 474:1 601:1 1314:1 1691:1 1774:1 1936:1 2250:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN MYH11) (NN mutation)) (VP (VBP appear) (VP (VBP contribute) (ADVP (RB also)) (NP (JJ human) (JJ intestinal) (NN neoplasia))))) |ET| |BS|18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 102:C04.588.274.476.411|ES| 2:1 5:1 19:1 34:1 36:1 109:1 450:1 640:1 1627:1 1691:1 2251:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN PPARgamma1)) (VP (MD might) (VP (VB offer) (NP (JJ promising) (NN gene) (JJ therapeutic) (NN target) (NN atherosclerosis))))) |ET| |BS|52:E02 149:G05.360.340.024.340.364.875.890 511:C14.907.137.126.307 513:C14.907.137.126|ES| 2:1 9:1 19:1 160:1 541:1 798:1 1042:1 1517:1 1691:1 1803:1 1804:1
-1 	|BT| (S (S (VP (TO To) (VP (VB characterize) (NP (NN CC531) (NN model) (JJ molecular) (NN level))))) (, ,) (NP (VBN screened) (NN mutation) (NN gene)) (VP (VBG covering) (NP (NP (JJ important) (NN signal-transduction) (NN pathway)) (NP (NP (VBN known) (NN play) (JJ major) (NN role) (NN colon) (NN carcinogenesis)) (, ,) (NP (NN wnt) (JJ ki-ras) (NN signaling) (NN pathway)))))) |ET| |BS|6:G05.360.340.024.340 15:F01.829.316.616 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 79:I03.450.642.693 126:G02.111.087.800 611:E05.599.595|ES| 2:1 9:1 19:1 31:1 34:1 72:1 113:1 161:1 195:1 207:1 238:1 249:1 383:1 462:1 556:1 828:1 902:1 2252:1 2253:1 2254:1 2255:1 2256:1 2257:1 2258:1
-1 	|BT| (S (S (VP (TO To) (VP (VB investigate) (NP (NP (NP (NN role) (NN APC) (NN gene) (NN microsatellite) (NN instability)) (PRN (-LRB- -LRB-) (NP (NN MI)) (-RRB- -RRB-))) (JJ PhIP-induced) (NN colon) (NN carcinogenesis))))) (, ,) (NP (NN mutation) (NN APC) (NN gene) (NN alteration) (NNS microsatellites)) (VP (VBN examined))) |ET| |BS|15:F01.829.316.616 18:G05.365.590 21:G05.360.340.024.340.375.249.050 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 394:G02.111.570.080.708.800.500 538:C23.550.362.590|ES| 2:1 9:1 10:1 11:1 14:1 19:1 31:1 34:1 113:1 207:1 324:1 459:1 828:1 951:1 1299:1 1332:1 1839:1 2259:1 2260:1
-1 	|BT| (NP (NP (NP (NNS Tumors)) (VP (VBG lacking) (S (NP (NN DNA) (NN mismatch) (NN repair) (NN activity) (-LRB- -LRB-) (NN MMR) (-RRB- -RRB-) (NN patient)) (NP (NP (NP (JJ Hereditary) (NN Nonpolyposis) (JJ Colorectal) (NN Cancer)) (PRN (-LRB- -LRB-) (NP (NN HNPCC)) (-RRB- -RRB-))) (SBAR (S (NP (JJ sporadic) (JJ colorectal) (NN cancer)) (VP (VBD identified) (NP (NP (NN presence) (JJ high) (NN level) (NN instability) (JJ repetitive) (NN sequence)) (VP (VBN known) (NP (NP (NNS microsatellites)) (PRN (-LRB- -LRB-) (NP (NN MSI)) (-RRB- -RRB-))))))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 50:M01.643 174:G02.111.087.219.220 394:G02.111.570.080.708.800.500 524:C04.588.274.476.411.307.190 538:C23.550.362.590 612:G02.111.570.080.708|ES| 10:1 14:1 17:1 18:1 19:1 53:1 120:1 178:1 249:1 293:1 346:1 376:1 399:1 513:1 556:1 584:1 623:1 666:1 725:1 1299:1 1919:1 2134:1 2136:1 2260:1 2261:1 2262:1 2263:1 2264:1 2265:1
-1 	|BT| (NP (NP (NNP UNLABELLED)) (: :) (NP (NP (NP (NN Loss) (NN E-cadherin)) (PRN (-LRB- -LRB-) (NP (NN CDH1)) (-RRB- -RRB-))) (, ,) (NP (NN Smad4)) (, ,) (NP (NP (NN p53) (VBN shown) (NN play) (JJ integral) (NN role)) (ADJP (JJ gastric))) (, ,) (NP (JJ intestinal) (, ,) (NN breast) (NN cancer) (NN formation)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 12:Z01.542.049 15:F01.829.316.616 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 70:A03.556.875.875 79:I03.450.642.693 613:D12.776.395.550.200.200|ES| 2:1 10:1 12:1 14:1 18:1 19:1 23:1 31:1 43:1 86:1 104:1 109:1 237:1 238:1 521:1 1788:1 2266:1 2267:1 2268:1 2269:1
-1 	|BT| (S (NP (NP (NN Up-regulation) (JJ several) (NN miR-1) (NN target)) (PP (VBG including) (NP (NP (NN FoxP1)) (, ,) (NP (NN MET)) (, ,) (NP (NN HDAC4) (JJ primary) (JJ human) (NNS HCCs) (NP (NN down-regulation) (NN expression) (JJ 5-AzaC-treated) (NN HCC) (NN cell)))))) (VP (VBP suggest) (NP (NN role) (NN hepatocarcinogenesis)))) |ET| |BS|15:F01.829.316.616 41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 104:C04.557.470.200.025.255 249:G05.355.315.800 339:G02.111.087.880|ES| 2:1 19:1 31:1 36:1 94:1 115:1 160:1 257:1 262:1 344:1 441:1 561:1 796:1 900:1 957:1 1132:1 2270:1 2271:1 2272:1 2273:1 2274:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD analyzed) (NP (NP (NN cooperation) (NN RB) (NN p53) (NN liver) (NN development) (NN pathogenesis)) (NP (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 104:C04.557.470.200.025.255 242:A03.620|ES| 12:1 19:1 35:1 303:1 304:1 501:1 836:1 843:1 1168:1 1209:1 1960:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD demonstrated) (SBAR (S (NN parkin) (: -) (: /) (: -) (NP (NN mouse) (VBD enhanced) (NN hepatocyte) (NN proliferation)) (VP (VBD developed) (NP (JJ macroscopic) (JJ hepatic) (NN tumor) (JJ characteristic) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 262:A11.436.348 515:C04.588.274.623|ES| 7:1 19:1 52:1 299:1 303:1 304:1 336:1 385:1 838:1 843:1 1165:1 1175:1 1909:1 2275:1 2276:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB first)) (VP (VBP show) (SBAR (S (NP (NP (NN Notch-1) (NN receptor)) (, ,) (NP (ADJP (RB well) (JJ downstream)) (NN target) (NN Hes-1)) (, ,)) (VP (VBD up-regulated) (NP (NP (NN colon) (NN cancer) (NN progression)) (, ,) (NP (NP (JJ similar) (NN gene)) (VP (VBN involved) (S (NP (NN chemoresistance))))))))))) |ET| |BS|6:G05.360.340.024.340 16:C23.550.291.656 142:I01.880.604 150:Z01.542.248.960|ES| 2:1 9:1 18:1 19:1 20:1 48:1 113:1 160:1 182:1 186:1 332:1 429:1 560:1 774:1 787:1 816:1 843:1 1301:1 2277:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD demonstrated) (NP (NP (NN enhancement) (NN Brf1) (NN Pol) (CD III) (NN gene) (NN expression)) (VBN associated) (NP (NP (NN occurrence) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 614:G05.360.340.024.340.364.875.667|ES| 9:1 10:1 14:1 19:1 52:1 115:1 169:1 303:1 304:1 441:1 843:1 1175:1 2278:1 2279:1 2280:1 2281:1 2282:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP document) (NP (NP (NN cooperation) (NN AEG-1) (NN c-Myc)) (VP (VBG promoting) (NP (NP (NN hepatocarcinogenesis) (VBG analyzing) (JJ hepatocyte-specific) (JJ transgenic) (NN mouse)) (VP (VBG expressing) (NP (CC either) (NP (NP (NN AEG-1)) (PRN (-LRB- -LRB-) (NP (NP (NN albumin)) (PRN (-LRB- -LSB-) (NP (NN Alb)) (-RRB- -RSB-))) (: /) (NP (NN AEG-1)) (-RRB- -RRB-))) (, ,) (NP (NP (NN c-Myc)) (PRN (-LRB- -LRB-) (NP (NN Alb/c-Myc)) (-RRB- -RRB-))) (, ,)))))) (PRN (-LRB- -LRB-) (NP (NNP Alb/AEG) (CD -1) (: /) (NN c-Myc)) (-RRB- -RRB-)))) |ET| |BS|99:B01.050.050.136.500 262:A11.436.348 615:D12.776.034|ES| 2:1 10:1 14:1 19:1 39:1 52:1 285:1 810:1 824:1 843:1 881:1 900:1 1373:1 1378:1 1960:1 1976:1 2283:1 2284:1 2285:1 2286:1 2287:1 2288:1 2289:1 2290:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD reported) (NP (NP (JJ hepatic) (NN coexpression) (NN c-Myc) (NN E2F1)) (, ,) (NP (CD 2) (JJ key) (NN regulator) (NN proliferation) (NN apoptosis)) (, ,) (NP (VBD enhanced) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN development) (JJ transgenic) (NN mouse))))) |ET| |BS|39:G04.299.139.160 99:B01.050.050.136.500 104:C04.557.470.200.025.255|ES| 2:1 10:1 14:1 19:1 35:1 52:1 89:1 148:1 159:1 235:1 285:1 299:1 303:1 304:1 385:1 441:1 824:1 838:1 843:1 993:1 1527:1 1961:1 2291:1
-1 	|BT| (NP (WHADVP (WRB When)) (NP (NP (NP (NN Apc) (NN gene) (NN knockout) (NN mouse)) (PRN (-LRB- -LRB-) (NP (NN APC1309) (NN mouse)) (-RRB- -RRB-))) (VP (VBN given) (NP (CD 600) (CD 1200) (NN p.p.m))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 21:G05.360.340.024.340.375.249.050 29:B01.050.050.136.500.500 193:C23.300.825.411 595:G07.203.650.240 596:E02.642.249 616:E05.318.780.074|ES| 2:1 5:1 9:1 10:1 14:1 19:1 29:1 52:1 71:1 109:1 170:1 202:1 280:1 289:1 369:1 370:1 646:1 647:1 781:1 783:1 2191:1 2292:1 2293:1 2294:1 2295:1 2296:1 2297:1 2298:1 2299:1 2300:1 2301:1
